期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物制剂与银屑病治疗

下载PDF
导出
摘要 银屑病是一种T淋巴细胞介导的慢性炎症性疾病,致病的记忆-效应T淋巴细胞集聚于病变皮肤并产生Ⅰ型细胞因子是发病机制的中心环节。基于银屑病发病机制中细胞免疫的关键步骤,研究开发了一些具有靶位特异性的生物制剂,这类药物无特定脏器毒性,具有安全、易耐受和使用方便的特点,为银屑病的长期治疗提供了安全有效的方案。根据作用靶点,可将药物分为抑制抗原呈递和共刺激、抑制T淋巴细胞活化和白细胞结合、直接杀伤活化T淋巴细胞、抑制炎症介质的活性和调节细胞因子平衡5类。
作者 林大东 唐耀琼
机构地区 第二军医大学附属长海医院皮肤科
出处 《世界临床药物》 CAS 2003年第8期462-466,共5页 World Clinical Drug
关键词 银屑病 生物制剂 重组人白细胞介素-10 达克珠单抗 地尼白介素-2 依那西普 奥普瑞白介素
分类号 R977 [医药卫生—药品] R758.63 [医药卫生—皮肤病学与性病学]
  • 相关文献

参考文献25

  • 1Liberopoulos EN;Drosos AA;Elisaf MS.Exacerbation of tuberculosis enteritis after treatment with infliximab,2002(07).
  • 2Schopf RE;Aust H;Knop J.Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha infliximab[J],2002(06).
  • 3Gottlieb AB;Masud S;Ramamurthi R.Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris[J],2003(01).
  • 4Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents[J],2002(01).
  • 5Gottlieb AB;Lebwohl M;Totoritis MC;etal.Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody[J],2002(05).
  • 6Asadullah K;Volk HD;Friedrich M.Experimental therapies for psoriasis,2002(06).
  • 7Schopf RE.IDEC-114 (IDEC),2001(05).
  • 8Abrams JR;Kelley SL;Hayes E;etal.Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA41g) reverses the cellular pathology of psoriatic plaques including the activation of keratinocytes dendritic cells and endothelial cells,2000.
  • 9Abrams JR;Lebwohl MG;Guzzo CA.CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris[J],1999(09).
  • 10Najafian N;Sayegh MH.CTLA4-1g:a novel immunosuppressive agent[J],2000(09).

二级参考文献19

  • 1[1]Luba KM,Stulberg DL.Chronic plaque psoriasis.Am Fam Physician,2006,73(4):636-644.
  • 2[4]Krueger JG.The immunologic basis for the treatment of psoriasis with new biologic agents.J Am Acad Dermatal,2002,46(1):1-23.
  • 3[5]Cball LA,Tso JY,Melrose J,et al.HuM291(Nuvion),a humanized Fc receptor-nonbinding antibody against CD3,anergizes peripheral blood T cells as partial agonist of the T cell receptor.Transplantation,2001,71(7):941-950.
  • 4[6]Skov L,Kragballe K,Zachariae C,et al.HuMax-CD4:a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.Arch Dermatol,2003,139(11):1433-1439.
  • 5[7]Bachelez H,Flageul B,Dubertret L,et al.Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4.J Autoimmun,1998,11(1):53-62.
  • 6[8]Gottlieb AB,Krueger JG,Wittkowski K,et al.Psoriasis as a model for T-cell-mediated disease:immunobiologic and clinical affects of treatment with multiple doses of efalizumab,an anti-CD11a antibody.Arch Dermatol,2002,1381(5):591-600.
  • 7[9]Krueger JG,Waiters IB,Miyazawa M,et al.Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor)on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.J Am Acad Dermatol,2000,43(3):448-458.
  • 8[10]da Silva AJ,Brickelmaier M,Majeau GR,et al.Alefacept,an immunomodulatory recombinant LFA-3/IgG1 fusion protein,induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+)cells.J Immunol,2002,168(9):4462-4471.
  • 9[11]Ellis CN,Krueger GG.Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.N Engl J Med,2001,345(4):248-255.
  • 10[13]Najafian N,Sayegh MH.CTLA4-Ig:a novel immanosuppressive agent.Expert Opin Investig Drugs,2000,9(9):2147-2157.

共引文献9

世界临床药物
2003年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部